Protara Therapeutics

“Protara is committed to identifying and advancing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs. Protara advances its investigational therapies, TARA-002 and IV Choline Chloride, by continuing to study them in clinical trials designed to evaluate potential efficacy, safety, and tolerability. Additional information about our ongoing clinical trials can be found on ClinicalTrials.gov. We maintain that the best way to make our investigational therapies available to patients is by enrolling and completing all of our clinical trials and, if those trials are successful, pursuing regulatory approval. However, in circumstances where patients are not eligible for our clinical trials and may not have options for alternative therapies, Protara evaluates requests to make its medicines available via expanded access for eligible patients. Expanded access, also called compassionate use, makes an investigational product available for treatment outside of clinical trials when no comparable or satisfactory alternative therapy option is available.”

OK-432 was studied in the largest ever conducted Phase 2 trials in LMs, in which the therapy was administered via a now-closed compassionate use program led by the University of Iowa.